Lecanemab scFv-Transferrin Fusion for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of transcytosis, limiting their efficacy and application in certain diseases.
Innovation Solution
A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of the transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake, and incorporating cleavable linkers that respond to specific cellular environments for targeted and controlled release of the therapeutic agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole antibodies are used for therapeutic treatment, then effector functions and half-life are improved, but penetration across biological barriers and tissue penetration are reduced
Solution Approach 1:
The antibody is segmented into smaller functional units: scFv (single-chain variable fragment) for antigen binding and transferrin for transcytosis. This segmentation allows the therapeutic agent to penetrate biological barriers while retaining binding functionality, resolving the contradiction between size and barrier penetration capability.
Solution Approach 2:
Transferrin acts as an intermediary that facilitates the transport of scFv across the blood-brain barrier and other biological barriers via transferrin receptor-mediated transcytosis. This intermediary mechanism enables small fragments to achieve targeted delivery without requiring the full antibody structure, resolving the size-penetration contradiction.
2Length of moving object
If scFv is used to improve tissue penetration and barrier crossing, then transcytosis capability is improved, but effector functions and half-life are reduced
Solution Approach 1:
The scFv and transferrin are merged into a single fusion protein construct. This combination allows the small scFv fragment to gain the transcytosis capability and extended circulation time of transferrin, compensating for the reduced half-life inherent to small fragments while maintaining barrier penetration advantages.
Solution Approach 2:
The transferrin component provides multiple functions: it serves as a transcytosis vehicle, extends circulation half-life through receptor recycling, and enables targeted delivery to TfR-expressing tissues. This multi-functionality compensates for the limitations of scFv alone, addressing both penetration and duration requirements.
3Quantity of substance
If antibodies are designed to cross the blood-brain barrier, then delivery to brain tissues is improved, but off-target effects and delivery to other tissues may increase
Solution Approach 1:
The fusion protein exhibits local quality by targeting specific tissues that express transferrin receptors (such as brain endothelial cells and certain cancer cells). The transferrin component provides localized recognition and binding to TfR in target tissues, enabling selective delivery while minimizing off-target effects in tissues with low or no TfR expression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-conjugated transferrin protein improves delivery across biological barriers, enhances therapeutic efficacy by reducing off-target effects, and ensures prolonged interaction with targets, thereby increasing treatment effectiveness.
Implementation Method 1
A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of the transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake
Implementation Method 2
incorporating cleavable linkers that respond to specific cellular environments for targeted and controlled release of the therapeutic agent
Data Source
AI summary
The efficacy and indication of lecanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.